NR1H4 and primary biliary cholangitis: ,11 The bile acid FXR agonist obeticholic acid (OCA) has been clinically validated in multiple phase II and III studies[12], [13], [14] and has been approved in combination with UDCA for patients with PBC having an inadequate response to UDCA or as monotherapy in patients intolerant of UDCA.15